Figure 8

DGLHD impaired DCs migratory capacity.
(A) The proportion of CD11c+CCR7+ DCs of NOD mice treated with DGLHD for 4 weeks from 8 until 12 weeks of age or model controls. (B) The proportion of CD11c+CFSE+ DCs migration to the normal mice mesenteric LN and inguinal LN. Data were presented as means ± SD (n = 3). *P < 0.05, **P < 0.01 compared with model control group.